Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hoping they provide an update soon

<< Previous

Bullboard Posts

Next >>

Comment by Duster340on Jun 07, 2021 1:06pm

116 Views

Post# 33340824

RE:RE:Hoping they provide an update soon

MrMugsy wrote:

markymark11 wrote: Would love to hear about their progress on the following items:

remaining ph3-enabling animal studies

tablet production and CMC

enhanced AME study

Of course, a surprise partnership announcement would be most welcome as well.

Agreed ... there's lots they may be able to share with us.

duster340 Writes: end of year financials were released on july 24th last year. likely will get some news that gets us moving the other way.

<< Previous

Bullboard Posts

Next >>

Victoria Gold stock falls 82% after Yukon landslide halts production